Article Text

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
  1. Masataka Kuwana1,
  2. Christiana Blair2,
  3. Tomohiko Takahashi3,
  4. Jonathan Langley4,
  5. John G Coghlan5
  1. 1 Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
  2. 2 Research and Development, Gilead Sciences, Inc, Foster City, California, USA
  3. 3 Medical Affairs, GlaxoSmithKline Plc, Tokyo, Japan
  4. 4 Medical Affairs, GlaxoSmithKline Plc, Brentford, London, UK
  5. 5 Cardiology Services, Royal Free Hospital, London, UK
  1. Correspondence to Professor Masataka Kuwana, Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan; kuwanam{at}nms.ac.jp

Abstract

Objectives To evaluate initial combination therapy with ambrisentan plus tadalafil (COMB) compared with monotherapy of either agent (MONO), and the utility of baseline characteristics and risk stratification in predicting outcomes, in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and the systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) subpopulation.

Methods This post hoc analysis of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) study included patients with CTD-PAH from the modified intention-to-treat population. Time to clinical failure (TtCF) was assessed by baseline characteristics, treatment assignment and risk group (low, intermediate and high) at baseline and week 16. TtCF was compared between groups using Kaplan-Meier curves and Cox proportional hazards regression modelling.

Results The analysis included 216 patients (COMB, n=117; MONO, n=99). The risk of clinical failure was lower with COMB versus MONO (risk reduction: CTD-PAH 51.7%, SSc-PAH 53.7%), particularly in patients with haemodynamic parameters characteristic of typical PAH without features of left heart disease and/or restrictive lung disease at baseline. The risk of clinical failure was lower with COMB versus MONO in the baseline low-risk group (HR not calculated due to no events in COMB), baseline intermediate-risk group (HR 0.519, 95% CI 0.297 to 0.905) and in the week 16 low-risk group (HR 0.069, 95% CI 0.009 to 0.548).

Conclusions The benefit of COMB over MONO was demonstrated in patients with CTD-PAH, particularly in those with typical PAH haemodynamic characteristics at baseline. COMB is appropriate for patients categorised as low risk and intermediate risk at baseline and low risk at follow-up.

Trial registration number NCT01178073.

  • arterial hypertension
  • outcomes research
  • systemic sclerosis
  • treatment
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Supplementary materials

Footnotes

  • Handling editor Josef S Smolen

  • Correction notice This article has been corrected since it published Online First. In table 1, the unit of PVR has been corrected and number of FC III in SSC/Mono amended.

  • Contributors All listed authors contributed substantially to the planning and implementation of this research. All authors revised the manuscript critically for important intellectual content, approved the final version for publication and agreed to be listed as authors.

  • Funding This study was funded by GlaxoSmithKline (study number 112565) and Gilead Sciences, Inc.

  • Competing interests MK has received personal fees from GSK, Bayer and Nippon Shinyaku, and research grants and personal fees from Actelion and Pfizer. CB is an employee and shareholder at Gilead Sciences. JL is a former employee and shareholder of GSK. TT is an employee at GSK. JGC has received research grants and personal fees from Actelion and GSK, and personal fees from Bayer, Endotronix, Pfizer and United Therapeutics.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles